The 340B Drug Pricing Program has been under scrutiny in recent years. In 2022 there have been some significant developments. Here is a recap of some of the key 340B Program headlines from this year so far. 340B Is Key in the Fight to End Viral...
2021 was an eventful year for the 340B Drug Pricing Program. The program was under scrutiny and there were significant developments around it as the country continued to navigate a global pandemic, economic recession, and a transition in power. Here is a recap of some...
SCL 340B Care is happy to share insights, news, and comments relevant to the 340B program to help you stay informed. Learn about current legislation, technology solutions, administrative challenges, and more that impact the program, safety net providers, drug manufacturers, and the health of Americans. Senate...
Recently, there has been an increase in legislative efforts for the 340B program. Lawmakers have introduced policies at the state level with the hope that they would prove successful and be adopted nationwide. Some of these efforts could greatly improve the benefits of safety net...
One year ago, The Medicare Negotiation and Competitive Licensing Act was introduced to increase transparency and allow the government to negotiate drug pricing with manufacturers. Recently, the Senate Finance Committee introduced the Prescription Drug Pricing Reduction Act of 2019 to address the high costs of...
Thirty years of claims processing experience makes SCL 340B CARE the ideal partner, providing an elite set of services for clients throughout the country. We are the leader in 340B program administration and continually build on this reputation through the constant expansion and excellence of...
The 340B Drug Discount Program has faced numerous attempts at regulatory changes in the last five years; one, in particular, challenged the Orphan Drug rule. The ruling stipulated that manufacturers are not required to provide covered entities orphan drugs under 340B, but a manufacturer may, at...
After President Trump entered office, the administration repeatedly delayed the implementation of a 340B rule that was finalized at the end of the Obama administration. Recently, the Trump administration has indicated that they plan to not only implement the rule but also accelerate...
Medicare patients could save an estimated $150 million on out-of-pocket co-payments for clinic visits if proposed changes to the hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Cancer (ASC) payment system are supported by the Centers for Medicare & Medicaid Services (CMS) for 2019. The...
In June, the Director of HRSA’s Office of Pharmacy Affairs, Captain Krista Pedley, testified before the U.S. Senate Committee On Health, Education, Labor, and Pensions. In her testimony, she stated, “Specific legislative authority to conduct rulemaking for all provisions in the 340B statute would be...